Patents by Inventor Jerome H. H. V. Custers

Jerome H. H. V. Custers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adenovirus and uses thereof
    Patent number: 11872281
    Abstract: Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: January 16, 2024
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Taco Gilles Uil, Soumitra Roy, Selina Khan, Jerôme H. H. V. Custers
  • Adenovirus and uses thereof
    Patent number: 11236361
    Abstract: Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: February 1, 2022
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Taco Gilles Uil, Soumitra Roy, Selina Khan, Jerôme H. H. V. Custers
  • Adenovirus and uses thereof
    Patent number: 11142551
    Abstract: Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: October 12, 2021
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Taco Gilles Uil, Soumitra Roy, Selina Khan, Jerôme H. H. V. Custers
  • ADENOVIRUS AND USES THEREOF
    Publication number: 20210214398
    Abstract: Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.
    Type: Application
    Filed: October 30, 2018
    Publication date: July 15, 2021
    Inventors: Taco Gilles UIL, Soumitra ROY, Selina KHAN, Jerôme H, H, V, CUSTERS
  • ADENOVIRUS AND USES THEREOF
    Publication number: 20210198690
    Abstract: Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.
    Type: Application
    Filed: October 30, 2018
    Publication date: July 1, 2021
    Inventors: Taco Gilles UIL, Soumitra ROY, Selina KHAN, Jerôme H, H, V, CUSTERS
  • ADENOVIRUS AND USES THEREOF
    Publication number: 20200323977
    Abstract: Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.
    Type: Application
    Filed: October 30, 2018
    Publication date: October 15, 2020
    Inventors: Taco Gilles UIL, Soumitra ROY, Selina KHAN, Jerôme H.H.V. CUSTERS
  • Recombinant adenovirus expressing two transgenes with a bidirectional promoter
    Patent number: 10570417
    Abstract: The invention provides recombinant adenovirus (rAd) and rAd vectors comprising a bidirectional mouse CMV (mCMV) promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such rAd and rAd vectors.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: February 25, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Kerstin Wunderlich, Jerôme H. H. V. Custers, Jort Vellinga, Barbara Petronella Sanders
  • Therapeutic HPV vaccine combinations
    Patent number: 10517944
    Abstract: Vectors, vaccines, vaccine compositions and vaccine combinations for use as therapeutics against HPV18 and/or HPV16 are described.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: December 31, 2019
    Assignees: Janssen Vaccines & Prevention B.V., Bavarian Nordic A/S
    Inventors: Evelien M. Bunnik, Jerôme H. H. V. Custers, Gerrit C. Scheper, Selina Khan, Markus Kalla, Katrin Weidner
  • Adenovirus based malaria vaccine encoding and displaying a malaria antigen
    Patent number: 10517938
    Abstract: The present invention relates to novel vaccines against malaria infections, based on recombinant adenovirus vectors. Described are capsid modified replication deficient adenovirus particle encoding and displaying circumsporozoite (CS) protein NANP-repeats (CSshort) from a malaria-causing parasite, preferably P. falciparum, via a minor capsid protein IX and encoding a heterologous protein as a transgene. In a particular embodiment, said replication incompetent vectors of rare serotypes such as human adenovirus 35 (HAdV35) and human adenovirus 26 (HAdV26) comprise nucleic acid encoding the CS protein, as a transgene, from a malaria-causing parasite and encoding and displaying the NANP-repeat from a malaria-causing parasite (1) directly fused to the protein IX, (2) fused to protein IX via a flexible linker or (3) an alpha-helical viral origin spacer SP1 to ensure both humoral and cellular responses against the selected antigens.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: December 31, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Jerôme H. H. V. Custers, Jort Vellinga, Marija Vujadinovic, Esmerelda Van Der Helm
  • THERAPEUTIC HPV VACCINE COMBINATIONS
    Publication number: 20190142933
    Abstract: Vectors, vaccines, vaccine compositions and vaccine combinations for use as therapeutics against HPV18 and/or HPV16 are described.
    Type: Application
    Filed: May 1, 2017
    Publication date: May 16, 2019
    Inventors: Evelien M. BUNNIK, Jerôme H.h.v. CUSTERS, Gerrit C. SCHEPER, Selina KHAN, Markus KALLA, Katrin WEIDNER
  • AN IMPROVED ADENOVIRUS BASED MALARIA VACCINE ENCODING AND DISPLAYING A MALARIA ANTIGEN
    Publication number: 20190083597
    Abstract: The present invention relates to novel vaccines against malaria infections, based on recombinant adenovirus vectors. Described are capsid modified replication deficient adenovirus particle encoding and displaying circumsporozoite (CS) protein NANP-repeats (CSshort) from a malaria-causing parasite, preferably P. falciparum, via a minor capsid protein IX and encoding a heterologous protein as a transgene. In a particular embodiment, said replication incompetent vectors of rare serotypes such as human adenovirus 35 (HAdV35) and human adenovirus 26 (HAdV26) comprise nucleic acid encoding the CS protein, as a transgene, from a malaria-causing parasite and encoding and displaying the NANP-repeat from a malaria-causing parasite (1) directly fused to the protein IX, (2) fused to protein IX via a flexible linker or (3) an alpha-helical viral origin spacer SP1 to ensure both humoral and cellular responses against the selected antigens.
    Type: Application
    Filed: January 19, 2017
    Publication date: March 21, 2019
    Inventors: Jerôme H.H.V. CUSTERS, Jort VELLINGA, Marija VUJADINOVIC, Esmerelda VAN DER HELM
  • Therapeutic HPV16 vaccines
    Patent number: 10071151
    Abstract: Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV16.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: September 11, 2018
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Evelien M. Bunnik, Jerome H. H. V. Custers, Gerrit C. Scheper, Koen Oosterhuis, Taco Gilles Uil, Selina Khan
  • RECOMBINANT ADENOVIRUS EXPRESSING TWO TRANSGENES WITH A BIDIRECTIONAL PROMOTER
    Publication number: 20180135075
    Abstract: The invention provides recombinant adenovirus (rAd) and rAd vectors comprising a bidirectional mouse CMV (mCMV) promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such rAd and rAd vectors.
    Type: Application
    Filed: April 12, 2016
    Publication date: May 17, 2018
    Inventors: Kerstin WUNDERLICH, Jerôme H.H.V. CUSTERS, Jort VELLINGA, Barbara Petronella SANDERS
  • THERAPEUTIC HPV16 VACCINES
    Publication number: 20170281747
    Abstract: Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV16.
    Type: Application
    Filed: May 22, 2017
    Publication date: October 5, 2017
    Inventors: Evelien M. BUNNIK, Jerome H.H.V. CUSTERS, Gerrit C. SCHEPER, Koen OOSTERHUIS, Taco Gilles UIL, Selina KHAN
  • VACCINE AGAINST RSV
    Publication number: 20150320854
    Abstract: Described is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises polynucleotide encoding a RSV F protein or immunologically active part thereof.
    Type: Application
    Filed: May 26, 2015
    Publication date: November 12, 2015
    Inventors: Katarina Radosevic, Jerome H.H.V. Custers, Jort Vellinga, Myra N. Widjojoatmodjo
  • Vaccine against RSV
    Patent number: 9125870
    Abstract: Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype 26 that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: September 8, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Katarina Radosevic, Jerome H. H. V. Custers, Jort Vellinga, Myra N. Widjojoatmodjo
  • Vaccine against RSV
    Patent number: 9119813
    Abstract: Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: September 1, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Katarina Radosevic, Jerome H. H. V. Custers, Jort Vellinga, Myra N. Widjojoatmodjo
  • Batches of recombinant adenovirus with altered terminal ends
    Patent number: 8932607
    Abstract: Described is a composition comprising a plurality of recombinant adenovirus particles, being a recombinant human adenovirus of serotype 5, 26, 34, 35, 48, 49 or 50, or a recombinant simian adenovirus, characterized in that the genomes of essentially all adenovirus particles in the composition comprise as the 5? terminal nucleotides the nucleotide sequence: CTATCTAT (nucleotides 1-8 of SEQ ID NO:7). Also described are methods to produce such compositions.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 13, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Jerome H. H. V. Custers, Jort Vellinga
  • VACCINE AGAINST RSV
    Publication number: 20140186391
    Abstract: Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.
    Type: Application
    Filed: March 22, 2013
    Publication date: July 3, 2014
    Applicant: CRUCELL HOLLAND B.V.
    Inventors: KATARINA RADOSEVIC, JEROME H. H. V. CUSTERS, JORT VELLINGA, MYRA N. WIDJOJOATMODJO
  • VACCINE AGAINST RSV
    Publication number: 20140147463
    Abstract: Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype 26 that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.
    Type: Application
    Filed: March 22, 2013
    Publication date: May 29, 2014
    Applicant: CRUCELL HOLLAND B.V.
    Inventors: KATARINA RADOSEVIC, JEROME H. H. V. CUSTERS, JORT VELLINGA, MYRA N. WIDJOJOATMODJO